Financial Data
REGN Financial Data
Revenue · Earnings · Margins · Balance Sheet · Cash Flow
REGNRegeneron Pharmaceuticals, Inc.
Healthcare / Biotechnology
Leader
Sector Leader
Latest quote
- Momentum95
- Value48
- Quality73
- Risk resilience61
- Sentiment—
Financial Data Overview
Detailed revenue, earnings, margins, balance sheet, cash flow, valuation metrics, technical indicators, and risk measures for deeper research.
Quarterly Financial Statements
Updated Oct 22, 2026.
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 |
|---|---|---|---|
| Revenue | $4.29B | $3.61B | $3.88B |
| Gross Profit | $3.71B | $2.94B | $3.3B |
| Operating Income | $1.42B | $642.9M | $879.9M |
| Net Income | $1.3B | $727.2M | $844.6M |
| EPS | $12.59 | $6.99 | $8.21 |
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 |
|---|---|---|---|
| Operating Cash Flow | $574.5M | $1.08B | $1.17B |
| Capital Expenditure | -$240.2M | -$230.6M | -$248.7M |
| Free Cash Flow | $334.3M | $848.3M | $922M |
| Net Cash Provided By Operating Activities | $574.5M | $1.08B | $1.17B |
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 |
|---|---|---|---|
| Total Assets | $41.73B | $40.87B | $40.56B |
| Total Debt | $1.99B | $2.71B | $2.71B |
| Cash And Cash Equivalents | — | — | — |
| Total Liabilities | $10.02B | $9.45B | $9.3B |
| Total Stockholders Equity | $31.71B | $31.42B | $31.26B |
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 |
|---|---|---|---|
| P/E ratio | 12.38 | 27.63 | 23.5 |
| P/B ratio | 2.03 | 2.56 | 2.54 |
| P/S ratio | 15.03 | 22.29 | 20.45 |
| Debt To Equity | 0.06 | 0.09 | 0.09 |
| Free Cash Flow Yield | 0.52% | 1.06% | 1.16% |
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 |
|---|---|---|---|
| P/E ratio | 12.38 | 27.63 | 23.5 |
| P/B ratio | 2.03 | 2.56 | 2.54 |
| P/S ratio | 15.03 | 22.29 | 20.45 |
| Return On Equity | 4.09% | 2.31% | 2.70% |
| Debt To Equity | 0.06 | 0.09 | 0.09 |
Current Stock Metrics
Current fundamental, technical, and risk readings in one place.
| Metric | Value |
|---|---|
| Pe | 19.67x |
| Pb | 2.69x |
| Gross Margin | 84.86% |
| Operating Margin | 25.56% |
| ROE | 13.81% |
| ROIC | 9.19% |
| Debt To Equity | 0.06 |
| FCF Yield | 4.15% |
As of Oct 21, 2026
| Metric | Value |
|---|---|
| Close | $805.67 |
| Volume | 578,415 |
| RSI (14) | 74.43 |
| MACD | 4.39 |
| MACD signal | -3.05 |
| MACD histogram | 7.44 |
| ADX (14) | 19.35 |
| SMA (50) | $790.97 |
| SMA (200) | $735.83 |
| ATR (14) | $21.28 |
| Historical volatility (annualized) | 31.23% |
| Volume (20-day average) | 692,603 |
As of Oct 21, 2026
| Metric | Value |
|---|---|
| Resilience score | 61/100 |
| Beta | 0.24 |
| Annual volatility | 33.45% |
| Max Drawdown | -26.05% |
| Sharpe Ratio | 1.05 |
| VaR (95%, 1-day) | -2.74% |
As of Oct 21, 2026
Detailed Metrics
Additional measures remain available here while the decision pages stay focused.
No additional fundamental metrics are available.
No additional technical indicators are available.
No additional risk measures are available.
Related Links
REGN Financial Data FAQ
What is Regeneron Pharmaceuticals, Inc.'s revenue?
Regeneron Pharmaceuticals, Inc.'s revenue is one of the core financial data points for REGN. Use it with revenue growth, margins, and EPS to understand whether sales are translating into earnings power.
Is Regeneron Pharmaceuticals, Inc.'s revenue growing?
Revenue growth shows whether Regeneron Pharmaceuticals, Inc. is expanding from prior periods. Compare growth with margins and free cash flow because faster sales growth is more valuable when profitability holds up.
What is REGN's EPS?
REGN's EPS, or earnings per share, helps connect net income to each share. EPS should be compared with EPS growth, P/E ratio, and analyst expectations.
What is Regeneron Pharmaceuticals, Inc.'s net income?
Regeneron Pharmaceuticals, Inc.'s net income shows profit after costs, taxes, and other expenses. It should be read with revenue, operating margin, EPS, and free cash flow.
How much free cash flow does Regeneron Pharmaceuticals, Inc. generate?
Free cash flow shows how much cash Regeneron Pharmaceuticals, Inc. generates after capital spending. It is useful for judging reinvestment capacity, buybacks, debt reduction, and valuation support.
How much cash and debt does Regeneron Pharmaceuticals, Inc. have?
Cash and debt help frame REGN's balance-sheet flexibility. Compare liquidity and leverage with free cash flow and profitability before judging financial strength.